Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

View Full Paper
Ask AI
Bookmark
Share

Authors

CRChristine E. RyanRRRobert ReddSPSamantha Pazienza

Discussion

Loading...

Member takes

Overview

Phase I/II trial shows high rates of MRD negative complete remission in mantle cell lymphoma, indicating effective therapy.

Key Points

  • Median overall survival was 86% in relapsed/refractory patients treated with the combination therapy.
  • The trial reported a high complete remission rate of 83% among treatment naïve patients with MCL.
  • Safety analysis revealed neutropenia in 46% and anemia in 29% of patients receiving the regimen.
  • The findings support the potential for less toxic, targeted therapy in mantle cell lymphoma treatment.

Cite This Study

Ryan et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8c9https://doi.org/10.1182/blood-2025-664
View Full Paper
Ask AI
Bookmark
Share